CD25在监测恶性肿瘤中的临床研究

目的探讨细胞膜白细胞介素2受体a链（CD25）与恶性肿瘤的病情变化及治疗预后间的关系。方法用流式细胞术测定155例恶性肿瘤病人及50例正常健康人的mIL—2Ra链（CD25）的结合表达率。结果恶性肿瘤病人明显低于正常对照组（P<0．05），恶性肿瘤病人化疗前明显低于化疗后（P<0．01），转移组明显低于无转移组（P<0．01）。结论检测CD25对恶性肿瘤病人的免疫治疗、病情判断及预后评估具有很重要的意义。

The Clinical Study on CD25 Determination in Malignant Tumor

To explore the relationship between the mIL-- ZRa chain(CD25) and the change ofdisease condition, prognosis of the treatment in malignant tumor. The expression rate of the mlLZRa chain in 155 malignant tumor patients and 50 healthy people was examined by using flow cytometry. The expression rate of malignant tumor patients was significantly lower than that of control (P<0.05). The patients of pre --chemotherapy was significantly lower than that of post--chemotherapy(P<0.01). The no metastatic group was significantly lower than that of metastatic group (P<0.01 ). It might be helpful of testing CD25 for immune treatment, condition judgement and prognosisevaluation in malignant tumor patients.